Peripheral Artery Disease Sub-Segment:
The peripheral artery disease (PAD) sub-segment is expected to witness substantial growth in the drug-coated balloon catheter market. Patients suffering from PAD often require treatment through angioplasty procedures. The drug-coated balloon catheter is highly effective in treating PAD as it helps in reducing restenosis rates and offers long-lasting outcomes. Moreover, the minimally invasive nature of the procedure and the shorter recovery time associated with it are driving the demand for drug-coated balloon catheters in the PAD sub-segment.
Coronary Artery Disease Sub-Segment:
The coronary artery disease (CAD) sub-segment is anticipated to showcase significant growth in the drug-coated balloon catheter market. CAD is a leading cause of mortality worldwide, and drug-coated balloon catheters play a crucial role in the treatment of this condition. They help in reducing the risk of restenosis and provide long-term outcomes. The increasing prevalence of CAD, advancements in drug-eluting technologies, and the growing adoption of minimally invasive procedures are fueling the demand for drug-coated balloon catheters in the CAD sub-segment.
The drug-coated balloon catheter market is highly competitive, with several prominent players operating in the industry. Some of the key market players include Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, Boston Scientific, iVascular, Medtronic plc, BIOTRONIK, Caliber Therapeutics, Concept Medical Research. These players are focusing on strategic collaborations, partnerships, and acquisitions to expand their product portfolio and strengthen their market presence. Additionally, continuous research and development activities to introduce innovative drug-coated balloon catheters with improved efficacy and safety profiles are key strategies adopted by these market players.